- A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia
- A Global Assessment of Medical, Emotional and Reproductive Concerns in Gestational Trophoblastic Disease Survivors
- Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment
- Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias
- Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia
- Camrelizumab Combined With Apatinib for Recurrent Resistant GTN
- Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia
- Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma （GTN） Patients With Score of 5-6
- Dactinomycin in Treating Patients With Persistent or Recurrent Gestational Trophoblastic Neoplasia
- Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia
- Letrozole as a Prophylaxis From GTN for Complete Mole Patients
- Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia
- Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy
- Phase 2 Trial for Chemo-Resistant Gestational Trophoblastic Neoplasias With Pembrolizumab (CR-GTP)
- Rescue Regimen and High Dose Methotrexate in Management of Presistent Gestational Trophoplastic Neoplasia
- Second Uterine Evacuation for Low-risk Gestational Trophoblastic Neoplasia
- Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule
- Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
- Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor
- Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy
- Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
- Surgery Plus Single Agent Chemotherapy Versus Primary Chemotherapy for Gestational Trophoblastic Neoplasms
- The French National Reference Centre of GTD
Clinical Trials
- 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
- A Phase I/II Study of Pembrolizumab and M032 (NSC 733972)
- A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
- A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
- A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
- A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
- A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
- Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
- AMG 102 and Avastin for Recurrent Malignant Glioma
- Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
- Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
- Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
- Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
- Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
- Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
- Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
- Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas
- Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
- Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
- AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme
- Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
- Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
- Bevacizumab Beyond Progression (BBP)
- Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
- Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme
- BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab
- BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
- CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
- Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM
- CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme
- Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
- Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
- Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme
- Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
- Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma
- Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
- Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
- Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
- Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
- Dose-Intense Temozolomide in Recurrent Glioblastoma
- Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
- DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
- Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
- EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma
- Engineered NK Cells Containing Deleted TGF-BetaR2 and NR3C1 for the Treatment of Recurrent Glioblastoma
- ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
- Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
- Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
- Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma
- Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients
- Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
- GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
- Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
- Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)
- Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
- GW572016 to Treat Recurrent Malignant Brain Tumors
- Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma
- Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
- Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue
- INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
- Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
- Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM
- Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
- Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide
- Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
- MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme
- Multi-site Validation and Application of a Consensus DSC-MRI Protocol
- Mycophenolate Mofetil Combined With Radiation Therapy in Recurrent Glioblastoma
- Natural Progesterone for the Treatment of Recurrent Glioblastoma
- Nedisertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
- Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme
- NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
- NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery
- ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
- Oncolytic Adenovirus DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
- Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
- Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
- Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Partial Brain Radiation Therapy, Temozolomide, Chloroquine, and Tumor Treating Fields Therapy for the Treatment of Newly Diagnosed Glioblastoma
- Pazopanib in Treating Patients With Recurrent Glioblastoma
- Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
- Pembrolizumab in Treating Patients With Recurrent Glioblastoma
- Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM
- Ph I Dasatinib + Erlotinib in Recurrent MG
- Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas
- Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
- Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
- Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma
- Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan
- Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
- Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
- Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas
- Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
- Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
- Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma
- Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
- Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma
- Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
- Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
- Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing Glioma
- Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
- Radiosurgery Plus Bevacizumab in Glioblastoma
- Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
- Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)
- Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
- Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
- Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
- Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
- Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
- Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
- Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma
- Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
- Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
- Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
- Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme
- SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
- Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
- Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
- Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy
- Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
- Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
- Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
- Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma
- Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
- Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel for Recurrent Glioblastoma
- Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
- Vaccine Therapy in Treating Patients With Recurrent Glioblastoma
- Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
- Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
- Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
- Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
- Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
- Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
- Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
- A Proof of Concept Study for 6 Month Treatment in Patients With C3 Glomerulopathy (C3G)
- A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
- A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN
- Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
- Cyclophosphamide and Fludarabine to Treat Lupus Nephritis
- Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis
- Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis
- Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis
- Efficacy of Pentoxifylline on Rapidly Progressive Glomerulonephritis
- Empagliflozin in Patients With Glomerulonephritis
- Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
- Evaluation of Clinical Efficacy of Pentoxifylline on Patients With Glomerulonephritis
- Immune System Related Kidney Disease
- Mesenchymal Stromal Cells (MSC´s) in Renal Lupus
- Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study
- Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis
- Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
- Plant Versus Animal Dietary Protein and the Effect on Proteinuria
- Predictors of Disease Progression in Primary Focal Segmental Glomerulosclerosis
- Recurrent Glomerulonephritis After Renal Transplantation
- Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease
- Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency
- Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy
- Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted
- Trial to Evaluate the Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE)
- Urinary T Lymphocytes Predict Renal Flares in Patients With Inactive ANCA-associated Glomerulonephritis
- US Time-Harmonic Elastography for the Early Detection of Childhood Glomerulonephritis
- Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney
- A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency
- Assessing a Risk Model for G6PD Deficiency
- Comparative Evaluation of the FINDER Instrument and FINDER G6PD Cartridge in Adults and Neonates
- Comparing G6PD Tests Using Capillary Blood Versus Venous Blood
- Diet Challenge in G6PD Deficient Egyptian Children: A One- Year Prospective Single Center Study With Genotype – Phenotype Correlation
- Effects of Alpha Lipoic Acid Supplementation in G6PD Deficient Individuals After Acute Exercise
- Effects of N-acetyl Cystein (NAC) Supplementation in G6PD Deficient Individuals After Acute Exercise
- Evaluation of a Diagnostic to Identify G6PD Deficiency in Brazil
- Evaluation of Different G6PD Testing Platforms
- G6PD Deficiency in Infarction Patients in Shaanxi Province
- Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers Receiving a Seven Day Dose Regimen
- Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand
- Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil
- Oxidative Stress, Carbohydrate Metabolism Disorders and G6PD Deficiency
- Pharmacokinetic and in Vitro Transmission Blocking Activities Study of Primaquine Compare to Methylene Blue in Healthy Volunteer Both G6PD Normal and G6PD Deficiency
- Primaquine Enantiomers in G6PD Deficient Human Volunteers
- Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)
- Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients
- Safety and Tolerability of Low Dose Primaquine
- Validation of a Diagnostic Test for Glucose-6-phosphate Dehydrogenase Deficiency in Anti-coagulated Blood
- Validation of Diagnostics to Identify Glucose-6-phosphate Dehydrogenase Activity in the US
- An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome
- Brain Metabolism Observed at 7 Tesla
- Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D
- Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
- Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)
- Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test
- Evaluation of Ketoflo
- Evaluation of Keyo in Children With Epilepsy
- Evaluation of Krio in Children and Adults With Epilepsy
- Ketonemia Through Menstrual Cycle
- Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
- Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS
- Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome
- Post Study Continuation of C7 for G1D
- Sodium Lactate Infusion in GLUT1DS Patients
- Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)
- The Glucose Transporter Type I Deficiency (G1D) Registry
- Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)
- Treatment Development of Triheptanoin (G1D)
- Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome
- Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)
- Energy Supplements to Improve Exercise Tolerance in Metabolic Myopathies
- Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses and Repeat Doses of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)
- Sleep and Quality of Life in Patients With Glycogen Storage Disease on Standard Versus Modified Uncooked Cornstarch
- Study to Evaluate Biomarkers and Clinical Manifestations in Individuals With Glycogen Storage Disease Type III (GSD III)